ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Rescue Protocol - 2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000206
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : November 7, 2016
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by:
University of California, Los Angeles

September 20, 1999
September 21, 1999
November 7, 2016
April 1991
August 2005   (Final data collection date for primary outcome measure)
  • Retention
  • Opiate use
  • Opiate craving
  • Adverse events
  • Opiate craving
  • Adverse events
  • Retention
  • Opiate use
Complete list of historical versions of study NCT00000206 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Clinical Rescue Protocol - 2
Clinical Rescue Protocol
The purpose of this study is to detect increasing medication dose results in heroin cessation for patients still using, to determine if decreasing medication dose in patients unable to tolerate medication dose increases retention, and to determine if blood levels of methadone or buprenorphine correlate with clinical response.
Not Provided
Interventional
Phase 2
Masking: Double
Primary Purpose: Treatment
Opioid-Related Disorders
Drug: Buprenorphine
Not Provided
Ling W, Shoptaw S, Wesson D, Rawson RA, Compton M, Klett CJ. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr. 1997;175:208-20. Review.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
Same as current
Not Provided
August 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

M/F ages 21-50. Opiate dependence according to DSM-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hynotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Sexes Eligible for Study: All
21 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000206
NIDA-06082-2
R18DA006082 ( U.S. NIH Grant/Contract )
R18-06082-2
Not Provided
Not Provided
Not Provided
Not Provided
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.
University of California, Los Angeles
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP